Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines.

Published

Journal Article

The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer provide evidence- and consensus-based recommendations for a multidisciplinary approach for the management of patients with gastric cancer. For patients with resectable locoregional cancer, the guidelines recommend gastrectomy with a D1+ or a modified D2 lymph node dissection (performed by experienced surgeons in high-volume centers). Postoperative chemoradiation is the preferred option after complete gastric resection for patients with T3-T4 tumors and node-positive T1-T2 tumors. Postoperative chemotherapy is included as an option after a modified D2 lymph node dissection for this group of patients. Trastuzumab with chemotherapy is recommended as first-line therapy for patients with HER2-positive advanced or metastatic cancer, confirmed by immunohistochemistry and, if needed, by fluorescence in situ hybridization for IHC 2+.

Full Text

Duke Authors

Cited Authors

  • Ajani, JA; Bentrem, DJ; Besh, S; D'Amico, TA; Das, P; Denlinger, C; Fakih, MG; Fuchs, CS; Gerdes, H; Glasgow, RE; Hayman, JA; Hofstetter, WL; Ilson, DH; Keswani, RN; Kleinberg, LR; Korn, WM; Lockhart, AC; Meredith, K; Mulcahy, MF; Orringer, MB; Posey, JA; Sasson, AR; Scott, WJ; Strong, VE; Varghese, TK; Warren, G; Washington, MK; Willett, C; Wright, CD; McMillian, NR; Sundar, H; National Comprehensive Cancer Network,

Published Date

  • May 1, 2013

Published In

Volume / Issue

  • 11 / 5

Start / End Page

  • 531 - 546

PubMed ID

  • 23667204

Pubmed Central ID

  • 23667204

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Language

  • eng

Conference Location

  • United States